Genmab A/S
GMAB28.660USD
-0.180-0.62%
終値 11/07, 16:00（ET）15分遅れの株価
17.65B時価総額
11.91直近12ヶ月PER
詳細情報 Genmab A/S 企業名
Genmab A/S is a Denmark-based international biotechnology company. It specializes in the creation and development of antibody therapeutics for the treatment of cancer. The Company is the creator of the approved antibodies: DARZALEX (daratumumab) for the treatment of certain multiple myeloma indications, Kesimpta for the treatment of adults with relapsing forms of multiple sclerosis, TEPEZZA (teprotumumab) for the treatment of thyroid eye disease and FASPRO, for the treatment of adult patients with certain multiple myeloma indications. The first approved Genmab created therapy Arzerra, approved for the treatment of certain chronic lymphocytic leukemia indications, is available in Japan and is also available in other territories via compassionate use or oncology access programs. Genmab develops a broad clinical and pre-clinical product pipeline, and owns four antibody technologies, DuoBody bispecific platform, HexaBody platform, DuoHexaBody platform & HexElect platform.
Genmab A/Sの企業情報
企業コードGMAB
会社名Genmab A/S
上場日Oct 01, 2000
最高経営責任者「CEO」Dr. Jan G.J. Van De Winkel, Ph.D.
従業員数2682
証券種類Ordinary Share
決算期末Oct 01
本社所在地Carl Jacobsens Vej 30
都市VALBY
証券取引所OMX Nordic Exchange Copenhagen A/S
国Denmark
郵便番号2500
電話番号4570202728
ウェブサイトhttps://www.genmab.com/
企業コードGMAB
上場日Oct 01, 2000
最高経営責任者「CEO」Dr. Jan G.J. Van De Winkel, Ph.D.
Genmab A/Sの経営陣
会社名
会社名/ポジション
ポジション
株式保有
変動額
Dr. Tahamtan (Tahi) Ahmadi, M.D., Ph.D.
Dr. Tahamtan (Tahi) Ahmadi, M.D., Ph.D.
Executive Vice President, Chief Medical Officer, Head of Experimental Medicines
Executive Vice President, Chief Medical Officer, Head of Experimental Medicines
--
--
Dr. Judith V. Klimovsky, M.D.
Dr. Judith V. Klimovsky, M.D.
Executive Vice President, Chief Development Officer
Executive Vice President, Chief Development Officer
--
--
Ms. Pernille Lyngvold Erenbjerg
Ms. Pernille Lyngvold Erenbjerg
Independent Deputy Chairman of the Board
Independent Deputy Chairman of the Board
--
--
Mr. Christopher Cozic
Mr. Christopher Cozic
Executive Vice President, Chief People Officer
Executive Vice President, Chief People Officer
--
--
Mr. Martin Schultz
Mr. Martin Schultz
Non-Independent Director, Employee Elected
Non-Independent Director, Employee Elected
--
--
Dr. Anders Gersel Pedersen, M.D., Ph.D.
Dr. Anders Gersel Pedersen, M.D., Ph.D.
Non-Independent Director
Non-Independent Director
--
--
Dr. Paolo Paoletti, M.D.
Dr. Paolo Paoletti, M.D.
Independent Director
Independent Director
--
--
Dr. Jan G.J. Van De Winkel, Ph.D.
Dr. Jan G.J. Van De Winkel, Ph.D.
President, Chief Executive Officer
President, Chief Executive Officer
--
--
Ms. Mijke Zachariasse, Ph.D.
Ms. Mijke Zachariasse, Ph.D.
Non-Independent Director, Employee Elected
Non-Independent Director, Employee Elected
--
--
Ms. Elizabeth A. O'farrell
Ms. Elizabeth A. O'farrell
Independent Director
Independent Director
--
--
詳細を見る
会社名
会社名/ポジション
ポジション
株式保有
変動額
Dr. Tahamtan (Tahi) Ahmadi, M.D., Ph.D.
Dr. Tahamtan (Tahi) Ahmadi, M.D., Ph.D.
Executive Vice President, Chief Medical Officer, Head of Experimental Medicines
Executive Vice President, Chief Medical Officer, Head of Experimental Medicines
--
--
Dr. Judith V. Klimovsky, M.D.
Dr. Judith V. Klimovsky, M.D.
Executive Vice President, Chief Development Officer
Executive Vice President, Chief Development Officer
--
--
Ms. Pernille Lyngvold Erenbjerg
Ms. Pernille Lyngvold Erenbjerg
Independent Deputy Chairman of the Board
Independent Deputy Chairman of the Board
--
--
Mr. Christopher Cozic
Mr. Christopher Cozic
Executive Vice President, Chief People Officer
Executive Vice President, Chief People Officer
--
--
Mr. Martin Schultz
Mr. Martin Schultz
Non-Independent Director, Employee Elected
Non-Independent Director, Employee Elected
--
--
Dr. Anders Gersel Pedersen, M.D., Ph.D.
Dr. Anders Gersel Pedersen, M.D., Ph.D.
Non-Independent Director
Non-Independent Director
--
--
収益内訳
通貨: USD更新時刻: Mon, Oct 6
通貨: USD更新時刻: Mon, Oct 6
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
事業別USD
会社名
収益
比率
Royalties
789.00M
85.30%
Net product sales
101.00M
10.92%
Collaboration revenue
21.00M
2.27%
Reimbursement income
13.00M
1.41%
Milestone payments
1.00M
0.11%
データなし
事業別
地域別
事業別USD
会社名
収益
比率
Royalties
789.00M
85.30%
Net product sales
101.00M
10.92%
Collaboration revenue
21.00M
2.27%
Reimbursement income
13.00M
1.41%
Milestone payments
1.00M
0.11%
株主
更新時刻: Sat, Nov 8
更新時刻: Sat, Nov 8
株主統計
種類
株主統計
株主統計
比率
AllianceBernstein L.P.
1.73%
Orbis Investment Management Ltd.
1.29%
Citadel Advisors LLC
0.58%
Arrowstreet Capital, Limited Partnership
0.56%
Two Sigma Investments, LP
0.56%
他の
95.28%
株主統計
株主統計
比率
AllianceBernstein L.P.
1.73%
Orbis Investment Management Ltd.
1.29%
Citadel Advisors LLC
0.58%
Arrowstreet Capital, Limited Partnership
0.56%
Two Sigma Investments, LP
0.56%
他の
95.28%
種類
株主統計
比率
Investment Advisor/Hedge Fund
4.32%
Investment Advisor
3.18%
Hedge Fund
2.35%
Research Firm
0.64%
Pension Fund
0.03%
Bank and Trust
0.02%
Family Office
0.01%
他の
89.45%
機関投資家保有株
更新時刻: Wed, Oct 1
更新時刻: Wed, Oct 1
報告期間
機関投資家数
保有株式数
比率
変動額
2025Q3
515
64.81M
10.54%
-15.68M
2025Q2
501
65.30M
10.31%
-6.21M
2025Q1
515
65.99M
10.42%
-5.32M
2024Q4
512
61.76M
9.33%
+621.44K
2024Q3
493
53.46M
8.41%
-4.14M
2024Q2
495
49.90M
7.86%
-6.30M
2024Q1
501
49.04M
7.53%
-7.16M
2023Q4
490
47.86M
7.32%
-6.37M
2023Q3
479
48.54M
7.43%
+204.98K
2023Q2
467
42.76M
6.55%
-5.77M
詳細を見る
株主動向
会社名
保有株式数
比率
変動額
変動率
日付
AllianceBernstein L.P.
10.66M
1.73%
-4.06M
-27.59%
Jun 30, 2025
Orbis Investment Management Ltd.
7.92M
1.29%
+2.21M
+38.69%
Jun 30, 2025
Citadel Advisors LLC
3.57M
0.58%
-857.47K
-19.37%
Jun 30, 2025
Arrowstreet Capital, Limited Partnership
3.45M
0.56%
+2.08M
+152.25%
Jun 30, 2025
Two Sigma Investments, LP
3.44M
0.56%
-433.92K
-11.20%
Jun 30, 2025
Harding Loevner LP
2.92M
0.48%
+42.61K
+1.48%
Jun 30, 2025
Renaissance Technologies LLC
2.77M
0.45%
+504.40K
+22.30%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
2.50M
0.41%
-443.29K
-15.04%
Jun 30, 2025
Marshall Wace LLP
1.91M
0.31%
-274.23K
-12.57%
Jun 30, 2025
First Trust Advisors L.P.
1.77M
0.29%
+60.50K
+3.54%
Jun 30, 2025
詳細を見る
関連ETF
更新時刻: Thu, Nov 6
更新時刻: Thu, Nov 6
銘柄名
比率
Tema Oncology ETF
5.08%
First Trust NYSE Arca Biotechnology Index Fund
4.45%
WisdomTree BioRevolution Fund
1.33%
iShares Biotechnology ETF
1.32%
AB Disruptors ETF
0.92%
First Trust NASDAQ BuyWrite Income ETF
0.29%
ProShares Ultra Nasdaq Biotechnology
0.13%
Invesco Nasdaq Biotechnology ETF
0.13%
ActivePassive International Equity ETF
0.13%
Avantis International Equity ETF
0.1%
詳細を見る
Tema Oncology ETF
比率5.08%
First Trust NYSE Arca Biotechnology Index Fund
比率4.45%
WisdomTree BioRevolution Fund
比率1.33%
iShares Biotechnology ETF
比率1.32%
AB Disruptors ETF
比率0.92%
First Trust NASDAQ BuyWrite Income ETF
比率0.29%
ProShares Ultra Nasdaq Biotechnology
比率0.13%
Invesco Nasdaq Biotechnology ETF
比率0.13%
ActivePassive International Equity ETF
比率0.13%
Avantis International Equity ETF
比率0.1%
配当金
過去5年間の配当金総支払額は
0.00
米ドルである。
日付
配当金
権利確定日
支払日
配当落ち日
データなし
株式分割
日付
種類
比率
データなし
日付
種類
比率
データなし
